Neurogene draws $200M PIPE ahead of next week’s Rett syndrome data

The U.S. election likely quieted most biotechs’ financial news this week, but a handful of companies still raised funds to support ongoing clinical and preclinical work.

Ahead of a presentation of data from its gene therapy for Rett syndrome, Neurogene Inc. (NASDAQ:NGNE) said Monday that a syndicate is providing $200 million in a PIPE deal to support further development. The biotech is preparing a registrational trial of the therapy, which uses an adeno-associated virus to deliver the MECP2 gene...